Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_1
1
33%
Ph phase_4
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

active_not_recruiting267%
not_yet_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
not_yet_recruitingphase_1

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

NCT07295873
active_not_recruitingnot_applicable

The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

NCT05797714
active_not_recruitingphase_4

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

NCT06743438

Clinical Trials (3)

Showing 3 of 3 trials
NCT07295873Phase 1

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide

Not Yet Recruiting
NCT05797714Not Applicable

The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.

Active Not Recruiting
NCT06743438Phase 4

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3